Transplantační medicína

Reduction in kidney function decline and risk of severe clinical events in Agalsidase beta–treated Fabry disease patients: a matched analysis from the Fabry Registry
Batista JL, et al. Clin Kidney J. 2024;17(8):sfae194.

Sanofi is committed to supporting patients with rare blood disorders. Here you can find all the information you need to get your patients started on ALPROLIX (eftrenonacog alfa) or ELOCTATE (efmoroctocog alfa).

Watch a 3-minute animated video explaining the mechanism of action (MOA) for extended half-life Fc-fusion factor replacement therapies.

ELOCTATE has been studied across a range of trials in both adults and children. Here you can read summaries of the publications and access links to the online manuscripts.

Download handy guides to dosing and delivery of ELOCTATE as well as a step-by-step patient guide to reconstitution.

A series of short videos with Prof. Hermans, Head of the Division of Haematology, the Thrombosis Unit as well as the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium.

Watch a 5-minute video on the role of factor IX and how ALPROLIX (eftrenonacog alfa) works in haemophilia B.

Download handy guides to dosing and delivery of ALPROLIX as well as a step-by-step patient guide to reconstitution.

A series of short videos with Prof. Hermans, Head of the Division of Haematology, the Thrombosis Unit as well as the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium.